StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) stock

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)

Close on Nov 17, 2026Market cap $287.64MP/E –Yield –

Emergent BioSolutions revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Emergent BioSolutions's revenue for the twelve months ending Sep 30, 2026 was $649.10M, down 17.7% year over year. For fiscal 2025 it was $742.90M, down 28.8% from the year before. Over ten years it grew 4.3% a year on average. The highest annual figure on record is $1.77B in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$742.90M-28.8%
FY2024Dec 31, 2024$1.04B-0.5%
FY2023Dec 31, 2023$1.05B-6.1%
FY2022Dec 31, 2022$1.12B-37.0%
FY2021Dec 31, 2021$1.77B+12.4%
FY2020Dec 31, 2020$1.58B+42.6%
FY2019Dec 31, 2019$1.11B+41.4%
FY2018Dec 31, 2018$782.40M+39.5%
FY2017Dec 31, 2017$560.90M+14.8%
FY2016Dec 31, 2016$488.80M-0.1%
FY2015Dec 31, 2015$489.33M+21.0%
FY2014Dec 31, 2014$404.47M+29.3%
FY2013Dec 31, 2013$312.75M+10.9%
FY2012Dec 31, 2012$281.89M+3.1%
FY2011Dec 31, 2011$273.38M-4.5%
FY2010Dec 31, 2010$286.17M+21.9%
FY2009Dec 31, 2009$234.79M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$110.00M-52.4%
Q2 FY2026Jun 30, 2026$234.30M+66.3%
Q1 FY2026Mar 31, 2026$156.10M-29.7%
Q4 FY2025Dec 31, 2025$148.70M-23.6%
Q3 FY2025Sep 30, 2025$231.10M-21.3%
Q2 FY2025Jun 30, 2025$140.90M-44.7%
Q1 FY2025Mar 31, 2025$222.20M-26.0%
Q4 FY2024Dec 31, 2024$194.70M-29.6%
Q3 FY2024Sep 30, 2024$293.80M+8.6%
Q2 FY2024Jun 30, 2024$254.70M-24.6%
Q1 FY2024Mar 31, 2024$300.40M+82.8%
Q4 FY2023Dec 31, 2023$276.60M-16.2%
Q3 FY2023Sep 30, 2023$270.50M+12.8%
Q2 FY2023Jun 30, 2023$337.90M+39.3%
Q1 FY2023Mar 31, 2023$164.30M-46.1%
Q4 FY2022Dec 31, 2022$330.20M-54.9%
Q3 FY2022Sep 30, 2022$239.90M-16.2%
Q2 FY2022Jun 30, 2022$242.60M-35.7%
Q1 FY2022Mar 31, 2022$304.80M-19.2%
Q4 FY2021Dec 31, 2021$732.90M+25.7%
Q3 FY2021Sep 30, 2021$286.30M-25.7%
Q2 FY2021Jun 30, 2021$377.40M-4.4%
Q1 FY2021Mar 31, 2021$377.00M+95.8%
Q4 FY2020Dec 31, 2020$583.00M+61.8%
Q3 FY2020Sep 30, 2020$385.20M+23.5%
Q2 FY2020Jun 30, 2020$394.70M+62.3%
Q1 FY2020Mar 31, 2020$192.50M+1.0%
Q4 FY2019Dec 31, 2019$360.40M+33.1%
Q3 FY2019Sep 30, 2019$311.80M+79.5%
Q2 FY2019Jun 30, 2019$243.20M+10.4%
Q1 FY2019Mar 31, 2019$190.60M+61.8%
Q4 FY2018Dec 31, 2018$270.70M+39.7%
Q3 FY2018Sep 30, 2018$173.70M+16.3%
Q2 FY2018Jun 30, 2018$220.20M+118.5%
Q1 FY2018Mar 31, 2018$117.80M+0.8%
Q4 FY2017Dec 31, 2017$193.80M+27.8%
Q3 FY2017Sep 30, 2017$149.40M–
Q2 FY2017Jun 30, 2017$100.80M–
Q1 FY2017Mar 31, 2017$116.90M–
Q4 FY2016Dec 31, 2016$151.66M–

More Emergent BioSolutions figures

See a number that looks wrong?